Type 1 Diabetes in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the type 1 diabetes market from 2023-2033.
This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for type 1 diabetes, covered in GlobalData’s report “Type 1 Diabetes: Seven-Market Drug Forecast and Market Analysis”, published in January 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare and POLI Price Intelligence databases. For more information on the methodology and assumptions used in GlobalData’s forecast extrapolations, please refer to the Methodology and Assumptions tabs in the Excel model for this report.
Scope
Overview of type 1 diabetes, including epidemiology, symptoms, diagnosis, and disease management.
Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
The diagnosed prevalence of T1D is expected to increase over the 10-year forecast period due changing population demographics, and an increased understanding of risk factors and environmental factors that may trigger the onset of T1D.
The potential launch of 5 disease-modifying therapeutics will increase the number of patients who, at diagnosis, can prolong their endogenous insulin secretion to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that find success in the market. The drive toward closed-loops systems, like an artificial pancreas, places a great need for ultra-fast insulins to launch in the market, and prompts more collaboration between across the industry.
Despite the variety of insulins currently available to T1D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 68MM type 1 diabetes therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 68MM type 1 diabetes therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Type 1 Diabetes (Juvenile Diabetes) reports